EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synergistic effect of PAK and Hippo pathway inhibitor combination in NF2-deficient Schwannoma

Dorothy Benton iD, Hoi Yee Chow, Sofiia Karchugina, Jonathan Chernoff

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0305121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Dorothy Benton und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry & Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America. Hauptthemen laut MEDLINE: Neurilemmoma, p21-Activated Kinases, Cell Proliferation, Hippo Signaling Pathway. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Children's Tumor Foundation, Ikena Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurofibromatosis type 2 is a genetic disorder that results in the formation and progressive growth of schwannomas, ependymomas, and/or meningiomas. The NF2 gene encodes the Merlin protein, which links cell cortical elements to the actin cytoskeleton and regulates a number of key enzymes including Group I p21-activated kinases (PAKs), the Hippo-pathway kinase LATS, and mTORC. While PAK1 and PAK2 directly bind Merlin and transmit proliferation and survival signals when Merlin is mutated or absent, inhibition of Group 1 PAKs alone has not proven sufficient to completely stop the growth of NF2-deficient meningiomas or schwannomas in vivo , suggesting the need for a second pathway inhibitor. As the Hippo pathway is also activated in NF2-deficient cells, several inhibitors of the Hippo pathway have recently been developed in the form of YAP-TEAD binding inhibitors. These inhibitors prevent activation of pro-proliferation and anti-apoptotic Hippo pathway effectors. In this study, we show that PAK inhibition slows cell proliferation while TEAD inhibition promotes apoptotic cell death. Finally, we demonstrate the efficacy of PAK and TEAD inhibitor combinations in several NF2-deficient Schwannoma cell lines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurilemmomap21-Activated KinasesCell ProliferationHippo Signaling PathwayNeurofibromin 2Signal TransductionProtein Serine-Threonine KinasesTranscription FactorsHumansCell Line, TumorApoptosisDrug SynergismNeurofibromatosis 2YAP-Signaling ProteinsProtein Kinase InhibitorsAdaptor Proteins, Signal TransducingDNA-Binding Proteins

Substanzen

p21-Activated KinasesNeurofibromin 2Protein Serine-Threonine KinasesTranscription FactorsNF2 protein, humanYAP-Signaling ProteinsProtein Kinase InhibitorsAdaptor Proteins, Signal TransducingDNA-Binding Proteins

Autor:innen und Institutionen

  • Department of Biochemistry & Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America.
  • Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America.

ORCID-Profile: Dorothy Benton

Förderung

  • Children's Tumor Foundation
  • Ikena Oncology

Zitieren

APA

Benton, D., Yee Chow, H., Karchugina, S., & Chernoff, J. (2024). Synergistic effect of PAK and Hippo pathway inhibitor combination in NF2-deficient Schwannoma. PLOS ONE. https://doi.org/10.1371/journal.pone.0305121

Vancouver

Benton D, Yee Chow H, Karchugina S, Chernoff J. Synergistic effect of PAK and Hippo pathway inhibitor combination in NF2-deficient Schwannoma. PLOS ONE. 2024. doi:10.1371/journal.pone.0305121

BibTeX
@article{Benton2024,
  author = {Benton, Dorothy and Yee Chow, Hoi and Karchugina, Sofiia and Chernoff, Jonathan},
  title = {Synergistic effect of PAK and Hippo pathway inhibitor combination in NF2-deficient Schwannoma},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0305121}
}
Kostenlos starten →